{
  "docId": "019dd923-622c-750b-8b97-e9d223c0ba42",
  "docSlug": "88a4417a0cf1",
  "documentTitle": "Apellis Pharmaceuticals (APLS)",
  "authorId": "52_Citron_Research",
  "authorName": "Citron Research",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-11-06 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77295077,
  "pageNumber": 12,
  "pageCount": 13,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "appendix_disclosure",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "Includes a specific reference to a 'Fonzi Scheme' analogy regarding One Reverse Mortgages.",
  "elementsJson": [
    "paragraph",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b97-e9d223c0ba42/12",
  "deckHref": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42#slide-12",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "In the end, Apellis and Syfovre might have the same fate as Henry Winkler last company he did commercial for, One Reverse Mortgages which ended up getting shut down mired by fraud lawsuits....Just another “Fonzi Scheme”",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-1ac1-76e9-bcd5-a0677b8513ea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.764,
        "x": 0.118,
        "y": 0.438
      },
      "kind": "disclaimer",
      "text": "These reports have been prepared by either Citron Research (\"Citron Research\") or Citron Capital, LLC (\"Citron Capital\")...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b886525b-d85e-4dd1-9271-59b561f613d6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.52,
        "x": 0.118,
        "y": 0.388
      },
      "kind": "paragraph",
      "text": "Cautious Investing To All..............Did somebody say 83%???",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "16b33a8c-33ea-44b0-b11b-5dab6594b650",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.055,
        "w": 0.764,
        "x": 0.118,
        "y": 0.145
      },
      "kind": "paragraph",
      "text": "It's highly likely that more will emerge about Apellis and Syfovre. Legal action seems imminent, and it won't be surprising if the FDA steps in with a warning label following a more thorough review of the drug.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "47d47447-5760-4031-b8f2-1377e29cadd9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.764,
        "x": 0.118,
        "y": 0.233
      },
      "kind": "paragraph",
      "text": "In the end, Apellis and Syfovre might have the same fate as Henry Winkler last company he did commercial for, One Reverse Mortgages which ended up getting shut down mired by fraud lawsuits....Just another \"Fonzi Scheme\"",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8f812f2d-55ed-48d7-a9b3-ea3f882c83ff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.022,
        "w": 0.115,
        "x": 0.118,
        "y": 0.108
      },
      "kind": "title",
      "text": "Conclusion",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "35228640-1538-4f0f-8173-c518fcee4d01",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 13,
      "from": 12,
      "beatId": "00cd5a6d-dcee-4fba-90ee-27fb59ffa2f9",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Victory",
      "beatSlug": "overcoming-monster-the-victory",
      "evidence": "Citron Research concludes with an expectation of regulatory action, framing it as a victory for their critical stance.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 13,
      "from": 1,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "1b08b18b-190c-48b4-b339-4e33de995cac",
      "evidence": "The document implies that failure to address Syfovre's complications could lead to regulatory action and reputational damage.",
      "position": 1,
      "objective": "What are the consequences of not taking action against Syfovre's safety concerns?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}